Rhythm Pharmaceuticals
RYTM
227 hedge funds and large institutions have $4.2B invested in Rhythm Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 93 increasing their positions, 74 reducing their positions, and 33 closing their positions.
43% more funds holding in top 10
Funds holding in top 10: 7 → 10 (+3)
26% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 74
22% more capital invested
Capital invested by funds: $3.44B → $4.2B (+$768M)
2.06% more ownership
Funds ownership: 102.53% → 104.59% (+2.1%)
0% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 33
0% less funds holding
Funds holding: 228 → 227 (-1)
62% less call options, than puts
Call options by funds: $13.8M | Put options by funds: $36.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$46M |
| 2 |
JP Morgan Chase
New York
|
+$39.2M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$31.5M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$20.9M |
| 5 |
ClearBridge Investments
New York
|
+$19.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
-$55.7M |
| 2 |
BlackRock
New York
|
-$36M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$36M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$32M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$18.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ET
251
Entropy Technologies
New York
| – | -$291K | -5,502 | Closed |
|
|
QC
252
Quadrature Capital
London,
United Kingdom
| – | -$280K | -5,278 | Closed |
|
253
Verition Fund Management
Greenwich,
Connecticut
| – | -$234K | -4,424 | Closed |
|
|
SP
254
SIH Partners
Wilmington,
Delaware
| – | -$211K | -3,980 | Closed |
|
|
BAMF
255
BI Asset Management Fondsmaeglerselskab
Kobenhavn,
Denmark
| – | -$34K | -648 | Closed |
|
256
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$2.54K | -48 | Closed |
|
|
CCM
257
Coldstream Capital Management
Bellevue,
Washington
| – | -$1.59K | -30 | Closed |
|
|
SC
258
Stephens Consulting
Flint,
Michigan
| – | -$1.06K | -20 | Closed |
|
|
HCP
259
Hexagon Capital Partners
Rogers,
Arkansas
| – | -$583 | -11 | Closed |
|
|
C
260
Covestor
London,
United Kingdom
| – | -$61 | -1 | -17% |
|
RYTM Hedge Fund Activity: Q2 2025 in Review
227 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q2 2025, worth a combined $4.2B — up 22% from $3.44B a quarter earlier.
Fund positioning in RYTM was balanced in Q2 2025: 33 funds opened new positions, 33 closed out, 93 added to existing stakes and 74 trimmed.
The largest buyer was Polar Capital Holdings, adding an estimated $46M. The largest seller was Primecap Management, cutting an estimated $55.7M.
- 227 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q2 2025, down from 228 in Q1 2025.
- Funds reported $4.2B of Rhythm Pharmaceuticals stock for Q2 2025, up 22% quarter-over-quarter.
- 33 funds opened new Rhythm Pharmaceuticals positions in Q2 2025 and 33 closed out, a net change of 0 holders.
- The largest Rhythm Pharmaceuticals buyer in Q2 2025 was Polar Capital Holdings, an estimated $46M added.
- The largest Rhythm Pharmaceuticals seller in Q2 2025 was Primecap Management, an estimated $55.7M sold.
Based on aggregated 13F filings for Q2 2025.